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Abstract
Purpose This pilot study aimed on generating insight on alterations in circulating immune cells during the use of FOL-
FIRINOX and gemcitabine/nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC).
Patients and methods Peripheral blood mononuclear cells were isolated before and 30 days after initiation of chemotherapy 
from 20 patients with advanced PDAC. Regulatory T cells (FoxP3+) and immune checkpoints (PD-1 and TIM-3) were 
analyzed by flow cytometry and immunological changes were correlated with clinical outcome.
Results Heterogeneous changes during chemotherapy were observed in circulating T-cell subpopulations with a pronounced 
effect on PD-1+ CD4+/CD8+ T cells. An increase in FoxP3+ or PD-1+ T cells had no significant effect on survival. An 
increase in TIM3+/CD8+ (but not TIM3+/CD4+) T cells was associated with a significant inferior outcome: median 
progression-free survival in the subgroup with an increase of TIM-3+/CD8+ T cells was 6.0 compared to 14.0 months in 
patients with a decrease/no change (p = 0.026); corresponding median overall survival was 13.0 and 20.0 months (p = 0.011), 
respectively.
Conclusions Chemotherapy with FOLFIRNOX or gemcitabine/nab-paclitaxel induces variable changes in circulating T-cell 
populations that may provide prognostic information in PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most 
lethal cancers of the gastrointestinal tract [1]. Combination 
chemotherapies with FOLFIRINOX [5-fluorouracil (5-FU), 
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folic acid, irinotecan, oxaliplatin] or gemcitabine/nab-pacli-
taxel are regarded as standard treatment options for advanced 
disease [2, 3]. Within the last years, checkpoint inhibitors have 
revolutionized anti-cancer treatments in multiple malignan-
cies. In contrast, efforts to develop successful immunothera-
peutic regimens for PDAC have largely failed so far [4]. Pre-
clinical studies suggested that chemotherapeutic drugs such 
as gemcitabine, oxaliplatin and 5-FU can have immunogenic 
effects mediated by the so-called “immunogenic cell death” 
[5–8]. For assessing the immunogenic status in peripheral 
blood multiple markers are available: well-known examples 
are forkhead box P3 (FoxP3), programmed cell death protein 
1 (PD-1) and T-cell immunoglobulin and mucin-domain con-
taining-3 (TIM-3). FoxP3 is essential for the differentiation of 
regulatory T cells (Tregs) and their inhibitory function. Previ-
ous studies have suggested a correlation of advanced PDAC 
stages with an increase in circulating Tregs [9, 10]. PD-1 is 
expressed on activated T cells and may form—together with its 
ligand PD-L1—an interaction that inhibits T cells activity [11, 
12]. TIM-3 is a regarded as a T-cell exhaustion marker (also 
expressed on dendritic cells, macrophages and B cells) and 
an increase of TIM-3 on tumor-infiltrating  CD3+ T cells was 
associated with a worse outcome in different tumor types (e.g. 
stomach or non-small cell lung cancer) [13, 14]. The goal of 
the present pilot study was thus to gain a better understanding 
of alterations in circulating T-cell subsets induced by standard 
chemotherapy regimens.
Materials and methods
We conducted a prospective, single-center study that included 
chemotherapy-naïve patients with cytologically or histologi-
cally confirmed advanced PDAC who received FOLFIRINOX 
or gemcitabine/nab-paclitaxel between 2015 and 2017. Blood 
samples (15 ml heparinized blood, 10 ml serum) were taken at 
day 1 and 30 of 1st-line chemotherapy. Ficoll density gradient 
separation was used to isolate peripheral blood mononuclear 
cells. After short-term storage at − 80 °C, flow cytometry 
was performed [using a LSR Fortessa flow cytometer (BD 
Biosciences)] to measure the expression of FoxP3, PD-1 and 
TIM-3 on CD3/CD4+ and CD3+/CD8+ T cells. To calculate 
the expression and the change in the expression within the first 
30 days, we used the following approach:
Calculation of the expression for the first point in time 
(before chemotherapy) and the second (during chemotherapy):
CD4 or CD8 positive cells
cell count CD3
× 100 = Expression 1 CD4 o. CD8 in percent,
Markerpositive cells
cell count CD4 or CD8
× 100 = Expression 1or 2 of a marker in percent.
Calculation of the change during time:
The clinical outcome was assessed by the endpoints 
progression-free survival (PFS) and overall survival (OS). 
PFS and OS were defined as the time interval from start of 
chemotherapy to documented disease progression or death 
from any cause. Patient follow-up was conducted until 
October 2019. Statistical analyses were performed using 
GraphPad Prism; time-to-event endpoints were analyzed 
by the Kaplan–Meier method, survival differences were 
compared using the log-rank test. This study had approval 
of the local ethics committee (approval number 284-10).
Results
Twenty-eight eligible patients were included in the study. 
For final analysis, patients were excluded if they died or 
were lost to follow-up before the second blood draw, had 
an intolerance towards one of the therapeutic agents or an 
infection (defined by clinical signs, laboratory parameters 
and/or the use of antimicrobial treatment) within the first 
30 days of chemotherapy. Finally, two consecutive blood 
samples were available for 20 patients (FOLFIRINOX: 
n = 17, gemcitabine/nab-paclitaxel: n = 3). Table 1 sum-
marizes the main clinical characteristics of the included 
patients: median age was 61 years and 19 out of 20 patients 
suffered from a ductal adenocarcinoma and 1 patient from 
a mixed adenoneuroendocrine carcinoma of the pancreas.
The analysis of the variability within T-cell subsets 
and the change of expression in Tregs and immune check-
point molecules during chemotherapy found changes in 
the expression of all markers: some patients showed a 
decrease or no change within the first 30 days and some 
patients showed an increase. Interestingly, we were not 
able to identify a specific pattern, e. g. an increase in reg-
ulatory T cells was not accompanied by an increase in 
immune checkpoints. Figure 1 illustrates the changes in 
the expression of T-cell markers during the first 30 days of 
chemotherapy. Specifically, regulatory T cells and PD-1+ 
T cells showed significant changes of up to 30% increase or 
decrease. In a second step, we analyzed whether a change 
Expression point of time 2 − Expression point of time 1
= change in the expression in percent.
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in the expression of a maker correlated with the patient`s 
clinical outcome. Regarding Tregs, PFS of patients with 
an increase in CD4+/FoxP3+ T cells was numerically 
shorter than of those who showed no change or a decrease 
in the expression (2.5 vs. 9.5 months). This difference, 
however, was not statistically significant (p = 0.263) 
(Fig. 2). Median OS in patients with an increase in CD4+/
FoxP3+ T cells was 14.5 vs. 15.5 months in patients with 
no change or a decrease (p = 0.787). There was no correla-
tion found between a change in CD8+ regulatory T cells 
and the outcome of patients (Fig. 2).
Patients with an increase of PD1+/CD4+ or PD-1+/
CD8+ T cells had a short median PFS (3.5  months). 
Patients without an increase in contrast had a median PFS 
of 9.5 months (p = 0.981 for PD1+/CD4+ and p = 0.902 for 
PD-1+/CD8+ ; see Fig. 3). Median OS was also numerically 
inferior in patients with an increase in PD-1 expression on 
CD4+ and CD8+ T cells (for CD4: 10.5 vs. 16.0 months, 
p = 0.725; for CD8: 8.0 vs. 18.0 months, p = 0.625; see 
Fig. 3).
As displayed in Fig. 4, the increase of TIM-3+/CD4+ T 
cells was associated with a numerically shorter PFS (median 
6.5 vs. 11.0 months, p = 0.331) and OS (median 13.5 vs. 
20.0 months, p = 0.240). An increase of TIM-3+/CD8+ T 
cells showed a statistically significant outcome correlation: 
median PFS in the group with an increase of TIM-3+/CD8+ 
T cells was 6.0 months compared to 14.0 months in patients 
with a decrease or no change (p = 0.026); the corresponding 
median OS was 13.0 months and 20.0 months, respectively 
(p = 0.011).
Discussion
Up to now, the effect of standard PDAC chemotherapy 
regimens on the patients’ immunological status (meas-
ured in circulating immune cells) remains widely unclear. 
However, these effects are of major scientific and clini-
cal interest as from these observations novel options may 
arise regarding immunotherapeutic approaches. In addi-
tion, the impact of chemotherapy on the “fitness” of T 
cells and other lymphocyte subpopulations might have 
important implications for the design of chimeric anti-
gen receptor (CAR) T cells trials in PDAC [15]. Differ-
ent preclinical studies suggested that chemotherapeutic 
drugs might promote anti-tumor immune response by 
induction of immunogenic cell death and immune activa-
tion [16]. To date, however, no supporting evidence for 
this hypothesis from prospective translational or clinical 
studies exists. In this pilot study, we found a high vari-
ability in the dynamic expression of markers for Tregs 
and T-cell checkpoint molecules during chemotherapy (see 
Fig. 1). As no specific pattern was obvious, these findings 
do not support the idea of a general immune modulatory 
effect of FOLFIRINOX or gemcitabine/nab-paclitaxel in 
advanced PDAC. Recently, the PA.7 randomized phase 
II study promoted the notion that the synergistic effect of 
immune checkpoint blockade observed in preclinical mod-
els might not be relevant in PDAC patients: in that trial, 
the addition of a dual immune checkpoint inhibition (with 
durvalumab and tremelimumab) to standard gemcitabine/
nab-paclitaxel did not improve outcome [17].
Table 1  Baseline patient characteristics (n = 20)
UICC Union for International Cancer Control, ECOG Eastern Coop-












 IV A 4 (20%)
 IV B 14 (70%)











Localization of distant metastases
 Liver 10 (50%)
 Non-liver 3 (15%)







Surgical therapy prior to inclusion in study
 Yes 10 (50%)
 No 10 (50%)
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Previous reports on immunological effects of gemcit-
abine-based chemotherapy in PDAC have found changes 
in Tregs in peripheral blood as an indicator for an acti-
vation of the immune system [18]. Lui and co-workers 
demonstrated that a decrease of circulating Tregs in 
patients with PDAC under chemotherapy was associated 
with an improved OS [10]. There is valid evidence that an 
increase in Tregs is associated with immunosuppression 
Fig. 1  Changes in the expression of regulatory T cells, PD-1+ T cells and TIM-3+ T cells divided in CD4+ and CD8+ subgroups. Patients 
marked with * received gemcitabine/nab-paclitaxel, all others FOLFIRINOX
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that may enhance tumor progression and, therefore, Tregs 
may present a predictor for worse outcome [19]. Within 
our pilot study, we, however, did not find clear evidence 
for an impaired prognosis in patients with an increase of 
either CD4+ or CD8+ Tregs during chemotherapy (Fig. 2). 
Regarding the course of PD-1+ T cells during chemother-
apy, only a non-significant trend between T-cell subsets and 
survival outcome was observed, with a poorer prognosis 
in patients with an increase of PD-1+ T cells under chem-
otherapy (Fig. 3). In line with those findings, Shen and 
colleagues recently reported a correlation between higher 
PDAC tumor stages and a high PD-1 expression on CD8+ 
T cells [20]. Also, the analysis of TIM-3 on CD4+ T cells 
showed a non-significant trend towards a worse prognosis 
in case of an increase of TIM-3+/CD4+ T cells. For an 
increase in TIM-3+/CD8+ T cells, a significant correla-
tion with a shorter PFS and OS was found. This finding is 
supported by a recent study that reported an association 
of TIM-3+ T cells in PDAC tumor tissue with a worse 
prognosis [21].
Fig. 2  Progression-free and overall survival in patients with an increase or decrease/no change in FoxP3+ Tregs over the first 30 days of chemo-
therapy
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A main limitation for our study arises from the 
rather low patient numbers that might also be a reason 
for the lacking statistical significance in some of the 
analysis on the prognostic impact of changes in circu-
lating immune cells (e.g. PD-1+ T cells). However, in 
contrast to other groups that recently reported similar 
observations (no significant effect of systemic chemo-
therapy for solid tumors on circulating T cells subsets), 
we focused on only one disease entity with all patients 
having an advanced stage of disease and investigated 
changes during chemotherapy with two well-established 
regimens [22]. In that context, the current pilot study 
yielded interesting insights into alterations in circulating 
immune cells during the use of standard PDAC chemo-
therapy and a prospective validation in a larger multi-
center cohort is recommended.
Fig. 3  Progression-free and overall survival in patients with an increase or decrease/no change in PD-1+/CD4+ or PD-1+/CD8+ T cells over 
the first 30 days of chemotherapy
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